MME and prostate carcinoma: We have previously demonstrated that recombinant NEP inhibits prostate cancer cell growth in vitro(3); overexpression of NEP using a tetracycline repressible system inhibits growth within the mouse prostate in an orthotopic prostate cancer model (8); and injection of Lentiviral-NEP into established xenograft tumors of the CWR22R castration-resistant prostate cancer subline 22RV1 significantly inhibited tumor growth (20).